Thomas A. Abrams

6.0k total citations
84 papers, 2.4k citations indexed

About

Thomas A. Abrams is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Thomas A. Abrams has authored 84 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 35 papers in Pulmonary and Respiratory Medicine and 23 papers in Surgery. Recurrent topics in Thomas A. Abrams's work include Colorectal Cancer Treatments and Studies (30 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (19 papers) and Hepatocellular Carcinoma Treatment and Prognosis (19 papers). Thomas A. Abrams is often cited by papers focused on Colorectal Cancer Treatments and Studies (30 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (19 papers) and Hepatocellular Carcinoma Treatment and Prognosis (19 papers). Thomas A. Abrams collaborates with scholars based in United States, France and Canada. Thomas A. Abrams's co-authors include Charles S. Fuchs, Jeffrey A. Meyerhardt, Andrew X. Zhu, Lawrence S. Blaszkowsky, David P. Ryan, Deborah Schrag, Brian M. Wolpin, Peter C. Enzinger, Jennifer A. Chan and Jeffrey W. Clark and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and JNCI Journal of the National Cancer Institute.

In The Last Decade

Thomas A. Abrams

81 papers receiving 2.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas A. Abrams United States	25	1.4k	698	668	655	367	84	2.4k
Renuka Iyer United States	31	1.5k 1.1×	573 0.8×	753 1.1×	755 1.2×	337 0.9×	178	3.0k
Cinzia Orlandini Italy	29	2.2k 1.6×	622 0.9×	877 1.3×	748 1.1×	217 0.6×	74	3.7k
Cristine Allmer United States	23	1.4k 1.0×	757 1.1×	599 0.9×	693 1.1×	1.1k 2.9×	84	2.9k
Andreas Schalhorn Germany	26	1.8k 1.3×	617 0.9×	811 1.2×	699 1.1×	255 0.7×	93	3.0k
Elizabeth Poplin United States	24	2.2k 1.6×	681 1.0×	1.2k 1.8×	721 1.1×	452 1.2×	80	3.2k
Petronella O. Witteveen Netherlands	29	2.0k 1.4×	807 1.2×	799 1.2×	702 1.1×	385 1.0×	95	3.8k
Efrat Dotan United States	23	1.6k 1.2×	706 1.0×	681 1.0×	1.2k 1.8×	381 1.0×	134	2.9k
Walid L. Shaib United States	25	1.4k 1.0×	552 0.8×	472 0.7×	964 1.5×	296 0.8×	129	2.5k
Luigi Manzione Italy	29	2.4k 1.7×	386 0.6×	1.3k 1.9×	637 1.0×	267 0.7×	88	3.4k
Annamaria Ferrero Italy	32	1.2k 0.8×	375 0.5×	373 0.6×	1.2k 1.9×	187 0.5×	168	3.4k

Countries citing papers authored by Thomas A. Abrams

Since Specialization

Citations

This map shows the geographic impact of Thomas A. Abrams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas A. Abrams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas A. Abrams more than expected).

Fields of papers citing papers by Thomas A. Abrams

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas A. Abrams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas A. Abrams. The network helps show where Thomas A. Abrams may publish in the future.

Co-authorship network of co-authors of Thomas A. Abrams

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas A. Abrams. A scholar is included among the top collaborators of Thomas A. Abrams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas A. Abrams. Thomas A. Abrams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Daneng, Farshid Dayyani, Devalingam Mahalingam, et al.. (2023). Final results of a phase 1b/2 study of tivozanib in combination with durvalumab in patients with advanced hepatocellular carcinoma in both previously untreated patients and patients progressing on atezolizumab and bevacizumab.. Journal of Clinical Oncology. 41(4_suppl). 585–585. 2 indexed citations

Iyer, Renuka, Daneng Li, Farshid Dayyani, et al.. (2022). Phase 1b/2 study of tivozanib in combination with durvalumab in subjects with advanced hepatocellular carcinoma (Deductive): Efficacy results in previously untreated patients.. Journal of Clinical Oncology. 40(4_suppl). 462–462. 1 indexed citations

Bockorny, Bruno, Andrea J. Bullock, Thomas A. Abrams, et al.. (2021). Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma. Digestive Diseases and Sciences. 67(7). 3455–3463. 4 indexed citations

He, Aiwu Ruth, Kabir Mody, Kevin Kim, et al.. (2021). A phase II study of atezolizumab (ATEZO) and bevacizumab (Bev) in combination with Y90 TARE in patients (Pts) with hepatocellular carcinoma (HCC).. Journal of Clinical Oncology. 39(3_suppl). TPS358–TPS358. 4 indexed citations

Goyal, Lipika, Cynthia A. Sirard, Michael Schrag, et al.. (2020). Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. Clinical Cancer Research. 26(23). 6158–6167. 46 indexed citations

Brown, Justin C., Sui Zhang, Jennifer A. Ligibel, et al.. (2020). Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. Cancer Prevention Research. 13(12). 1055–1062. 31 indexed citations

Iyer, Renuka, Daneng Li, Farshid Dayyani, Michael N. Needle, & Thomas A. Abrams. (2020). A phase Ib/II, open-label study of tivozanib in combination with durvalumab in subjects with untreated advanced hepatocellular carcinoma.. Journal of Clinical Oncology. 38(15_suppl). e16599–e16599. 2 indexed citations

Yurgelun, Matthew B., Anu Chittenden, Chinedu Ukaegbu, et al.. (2018). Implementing universal genetic counseling (GC) and multigene germline testing (MGT) for pancreatic cancer (PC) patients (pts).. Journal of Clinical Oncology. 36(15_suppl). 1512–1512. 3 indexed citations

Eads, Jennifer R., Stacey Stein, Anthony B. El-Khoueiry, et al.. (2017). A phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) for first-line therapy with advanced biliary tract cancer (BTC).. Journal of Clinical Oncology. 35(15_suppl). 4075–4075. 3 indexed citations

10.

Abrams, Thomas A., Gary Meyer, Jeffrey A. Meyerhardt, et al.. (2017). Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer. The Oncologist. 22(8). 925–933. 38 indexed citations

11.

McAdam, Laura, Jenny Setchell, Patricia Thille, et al.. (2017). The impact of an interdisciplinary DMD clinic model on volume of care recommendations. Neuromuscular Disorders. 27. S100–S100. 1 indexed citations

12.

Eads, Jennifer R., Stacey Stein, Anthony B. El-Khoueiry, et al.. (2016). Phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer (ABC). Annals of Oncology. 27. vi235–vi235. 4 indexed citations

13.

Brooks, Gabriel A., Thomas A. Abrams, Jeffrey A. Meyerhardt, et al.. (2014). Identification of Potentially Avoidable Hospitalizations in Patients With GI Cancer. Journal of Clinical Oncology. 32(6). 496–503. 120 indexed citations

14.

Goyal, Lipika, Raymond Wadlow, Lawrence S. Blaszkowsky, et al.. (2014). A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma. Investigational New Drugs. 33(1). 128–137. 42 indexed citations

15.

Wolpin, Brian M., Kimmie Ng, Andrew X. Zhu, et al.. (2013). Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer. The Oncologist. 18(4). 377–378. 38 indexed citations

16.

Zhu, Andrew X., Marek Ancukiewicz, Jeffrey G. Supko, et al.. (2013). Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. Clinical Cancer Research. 19(6). 1557–1566. 55 indexed citations

17.

Abrams, Thomas A., et al.. (2011). Patterns of Adjuvant Chemotherapy Use in a Population-Based Cohort of Patients With Resected Stage II or III Colon Cancer. Journal of Clinical Oncology. 29(24). 3255–3262. 48 indexed citations

18.

Faris, Jason E., Jamie Arnott, Hui Zheng, et al.. (2011). A phase 2 study of oral MKC-1, an inhibitor of importin-β, tubulin, and the mTOR pathway in patients with unresectable or metastatic pancreatic cancer. Investigational New Drugs. 30(4). 1614–1620. 6 indexed citations

19.

Enzinger, Peter C., D. P. Ryan, Eileen Regan, et al.. (2008). Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer. Journal of Clinical Oncology. 26(15_suppl). 4552–4552. 36 indexed citations

20.

Wang, Richard Y., et al.. (1999). The Effects of Colchicine Treatment on Wound Healing in a Caustic Murine Injury Model. Journal of Toxicology Clinical Toxicology. 37(7). 845–853. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact